Discovery of CFTR modulators for the treatment of cystic fibrosis

M Lopes-Pacheco, N Pedemonte… - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction Cystic fibrosis (CF) is a life-threatening inherited disease caused by mutations
in the gene encoding the CF transmembrane conductance regulator (CFTR) protein, an …

Small-molecule drugs for cystic fibrosis: Where are we now?

O Laselva, L Guerra, S Castellani, M Favia… - Pulmonary …, 2022 - Elsevier
The cystic fibrosis (CF) lung disease is due to the lack/dysfunction of the CF Transmembrane
Conductance Regulator (CFTR), a chloride channel expressed by epithelial cells as the …

Pharmacological modulation of ion channels for the treatment of cystic fibrosis

MC Pinto, IAL Silva, MF Figueira… - Journal of …, 2021 - Taylor & Francis
Cystic fibrosis (CF) is a life-shortening monogenic disease caused by mutations in the gene
encoding the CF transmembrane conductance regulator (CFTR) protein, an anion channel …

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?

KE Oliver, MS Carlon, N Pedemonte… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Cystic fibrosis (CF), a potentially fatal genetic disease, is caused by loss-of-
function mutations in the gene encoding for the CFTR chloride/bicarbonate channel …

The use of pharmacological chaperones in rare diseases caused by reduced protein stability

J Gil‐Martínez, G Bernardo‐Seisdedos, JM Mato… - …, 2022 - Wiley Online Library
Rare diseases are most often caused by inherited genetic disorders that, after translation,
will result in a protein with altered function. Decreased protein stability is the most frequent …

[HTML][HTML] Identification of novel F508del-CFTR traffic correctors among triazole derivatives

M Bacalhau, FC Ferreira, A Kmit, FR Souza… - European Journal of …, 2023 - Elsevier
The most prevalent cystic fibrosis (CF)-causing mutation–F508del–impairs the folding of
CFTR protein, resulting in its defective trafficking and premature degradation. Small …

Preclinical studies of a rare CF-causing mutation in the second nucleotide binding domain (c. 3700A> G) show robust functional rescue in primary nasal cultures by …

O Laselva, J McCormack, C Bartlett, W Ip… - Journal of Personalized …, 2020 - mdpi.com
The combination therapies ORKAMBITM and TRIKAFTATM are approved for people who
have the F508del mutation on at least one allele. In this study we examine the effects of …

Structural Comparative Modeling of Multi-Domain F508del CFTR

EF McDonald, H Woods, ST Smith, M Kim… - Biomolecules, 2022 - mdpi.com
Cystic fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR), an epithelial anion channel expressed in …

[HTML][HTML] PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p. Phe508del-CFTR

FC Ferreira, MD Amaral, M Bacalhau… - European Journal of …, 2024 - Elsevier
The deletion of a phenylalanine at position 508 (p. Phe508del) in the CFTR anion channel is
the most prevalent variant in people with Cystic Fibrosis (CF). This variant impairs folding …

Additive potentiation of R334W-CFTR function by novel small molecules

M Bacalhau, FC Ferreira, IAL Silva… - Journal of Personalized …, 2023 - mdpi.com
The R334W (c. 1000C> T, p. Arg334Trp) is a rare cystic fibrosis (CF)-causing mutation for
which no causal therapy is currently approved. This mutation leads to a significant reduction …